Clinical Trial Update: Celecoxib and Erlotinib in Treating Patients With Liver Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating the combination of celecoxib and erlotinib for liver cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Liver Cancer | Phase 1, Phase 2 | Status: WITHDRAWN